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Total Thyroidectomy: The Procedure of 
Choice for Toxic Goitre
Mohamad Hussain and Abdullah N. Hisham, Department of Breast and Endocrine Surgery, 
Putrajaya Hospital, Putrajaya, Malaysia.
OBJECTIVE: Over the years, subtotal thyroidectomy has been the mainstay of treatment for toxic goitre;
however, total thyroidectomy is increasingly being considered as the procedure of choice. This study
aimed to review our experience with total thyroidectomy in toxic goitre and evaluate the outcome of this
procedure.
METHODS: A total of 67 consecutive patients who were diagnosed with toxic goitres and had total thy-
roidectomy from January 2003 to February 2005 were included in this prospective open study. The pre-
operative diagnosis in all patients was benign goitre. The surgical outcomes were reviewed with regard to
mortality and morbidity.
RESULTS: A standardized operative technique was adopted and practiced among all surgeons in our
department. Of the 67 patients with toxic goitre, 36 (53.7%) patients had toxic multinodular goitre
(Plummer’s disease) and 31 (46.3%) patients had diffuse goitre (Graves’ disease). Although there were no
documented injuries to the recurrent laryngeal nerves, one patient had temporary hoarseness of voice. 
In our series of total thyroidectomy, 18 patients (26.8%) developed transient hypocalcaemia but only one
patient (1.5%) had persistent hypocalcaemia. Four (5.9%) patients had occult papillary thyroid cancer and 
one patient (1.5%) had Hashimoto’s thyroiditis discovered on histological examination. There were no
other postoperative complications except for wound infection in one patient (1.5%).
CONCLUSION: Total thyroidectomy should be considered as the procedure of choice for toxic goitres.
It is paramount that sufficient attention be paid to the preservation of the laryngeal nerves and the
parathyroid glands. [Asian J Surg 2008;31(2):59–62]
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Introduction
Over the years, subtotal thyroidectomy (STT) has become
the mainstay of treatment for toxic goitre; however, total
thyroidectomy (TT) is now increasingly being consid-
ered.1,2 STT has been the standard procedure as it was
thought to avoid long-term thyroxine replacement therapy
and presumed to be a safer operation with low complication
rates compared to TT. But on the contrary, the long-term
results of STT are not without their consequences. This 
is evidenced by the progressive increase in the incidence
of hypothyroidism and recurrent hyperthyroidism from
remnant thyroid tissue left behind.3,4
On the other hand, the advantages of TT are that it
avoids recurrent disease and future repeat thyroidectomy,
which is known to be associated with higher morbidity
even if performed with great care and skill. If the risk of
complications from TT is no higher than that from STT,
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and coupled with significant advantages in the prevention
of recurrence and avoidance of repeat surgery, perhaps TT
should be considered as a treatment option for toxic goitre.
Moreover, TT is increasingly being accepted as the pro-
cedure of choice for toxic multinodular goitre (MNG)
involving both lobes, particularly those with significant
compression symptoms.5,6
This paper provides a wider perspective of TT as the
choice of treatment for toxic MNG and diffuse goitre and
evaluates the outcome of this procedure in our institu-
tion. It is hoped that this paper can answer the question
as to whether or not TT should be considered as the pro-
cedure of choice in the management of all toxic goitres.
Patients and methods
All patients who were diagnosed with toxic goitre (Graves’
disease or Plummer’s disease) and who underwent TT
between January 2003 and February 2005 were included
in this prospective open study. Graves’ disease was diag-
nosed based on the clinical presentation of thyrotoxico-
sis, either in the presence of a diffuse goitre with or without
thyroid eye signs and symptoms. The preoperative diagno-
sis in all patients was benign goitre. All repeat surgery for
toxic goitres was excluded from this study.
Bilateral recurrent laryngeal nerves were routinely
identified and preserved during surgery. Identification of
all parathyroid glands was attempted and preserved in all
patients, but inadvertently removed or devascularized
parathyroid glands were routinely autotransplanted into
the neck muscle. Routine measurement of serum calcium
was performed within 6 hours of the operation and at
least once daily until stabilization before discharge. Calcium
supplement and vitamin D analogue were given to patients
with symptoms of hypocalcaemia or low serum calcium
level <1.8 mmol/L. Those who needed the supplement for
less than 12 months after the operation were defined as
having temporary hypocalcaemia. Permanent hypocal-
caemia was defined as the need for calcium supplement
for more than 12 months after operation and a low serum
calcium level.
Specific data obtained were patient demographics, indi-
cation for the operations, operative details, postoperative
complications and long-term outcome. Complete follow-
up data with respect to postoperative hypocalcaemia were
retrieved and all patients were followed-up for a minimum
of 12 months.
Results
During the study period, 67 consecutive patients under-
went TT. Their median age was 38 years (range, 22–68 years),
and the female:male ratio was 5:1. Of the 67 patients, 31 were
diagnosed with Graves’ disease and 36 with Plummer’s dis-
ease. Fifteen patients had severe eye signs (orbitopathy), 10
of whom had Graves’ disease. The main indications for sur-
gery were failed medical treatment (86%), significant com-
pression symptoms (33%), or substernal extension of the
goitre. All the patients who failed medical therapy were
treated with neomecazole and propranolol for at least two
courses.
A total of 134 avascular (cricothyroid) spaces were clearly
identified during operation and 91 (68%) of the external
laryngeal nerves were identified and classified. According
to the proposed classification, 20 (15%) of the nerves were
type 1, 41 (31%) of the nerves were type 2a, and 30 (22%)
were type 2b.7 All the recurrent laryngeal nerves were iden-
tified, with the majority of them (70%) being a single branch,
which coursed along the tracheal oesophageal groove.8
The morbidity of transient hypocalcaemia occurred in 18
of 67 (26.8%) patients. Although there were no documented
injuries to the recurrent laryngeal nerves, one (1.5%) patient
had temporary hoarseness of the voice. This patient had
prolonged intubation in the intensive care unit before and
after operation because of severe compressive symptoms.
In addition, this particular patient had developed thyroid
storm before the operation, which continued in the post-
operative course. One (1.5%) patient also developed minor
wound infection, which resolved with antibiotic therapy.
Permanent hypocalcaemia was uncommon and occurred
in only one (1.5%) patient in our series. There was no perma-
nent recurrent laryngeal nerve palsy or mortality in this
series. It is interesting to note that in a few patients, there
were incidental findings in the histopathology report other
than toxic goitre: papillary thyroid carcinoma in four (6%)
patients, and underlying Hashimoto’s thyroiditis in one
(1.5%), as shown in the Table.
Discussion
Whether or not TT should be the preferred treatment of
choice for all toxic goitres remains controversial, although
there is an increasing number of reports recommending
its use for the disease.1,2 More importantly is that STT,
which leaves behind the posterior nodules (Zuckerkandl
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tubercle), may account for a substantial incidence of recur-
rence and persistence compression symptoms.9,10 We would
emphasize that at least 33% of our patients had either sig-
nificant compression symptoms or substernal extension
of the toxic goitre, which required at least TT as the pro-
cedure of choice. Fifteen patients who were referred by an
ophthalmologist for surgery had orbitopathy, in particu-
lar, proptosis; 10 patients were diagnosed with Graves’
disease and five with toxic MNG.
We adopted TT for both toxic MNG and Graves’ disease.
The surgery for toxic goitre is very challenging due to the
highly vascularized gland. Our main concern here was to
evaluate the safety of the operation, which was the aim of
this study. STT has been the mainstay for the surgical
management of toxic goitre in many centres and is advo-
cated in the belief that it avoids prolonged thyroxine
replacement therapy whilst being a relatively safe opera-
tion with low complication rates. In STT, limited dissec-
tion is performed in the tracheo-oesophageal grooves and
it is presumed that there is minimal risk of damaging the
recurrent laryngeal nerve and the parathyroid glands.
Therefore, it is presumed to be a safer operation than TT.
However, there is an increasing number of reports of
recurrent toxic goitre from remnant thyroid tissue after
STT and increasing incidence of hypothyroidism on long-
term follow-up. It is interesting to learn that with a longer
follow-up period, more patients with abnormal thyroid
function are detected. Dominello et al showed a progres-
sive onset of both hypothyroidism and recurrent hyper-
thyroidism with time.4 The proportion of patients with
hypothyroidism increased from 48.5% at 6 months to 69.3%
at 15 years after STT.
In contrast, thyroid function is more predictable after
TT and can be easily maintained with thyroxine replace-
ment. In fact, hypothyroidism should be regarded as an
endpoint of surgical treatment rather than a complication
of TT. Furthermore, TT and thyroxine therapy allows
rapid control and return to the normal euthyroid state,
with no possibility of recurrent hyperthyroidism. Hence,
it provides a more certain surgical outcome than STT.
In our centre, we have stopped performing STT so we
do not have data to compare with the outcome of TT.
Nonetheless, when we compare our outcome of TT with
other endocrine centres, our results are comparable. Many
studies have found no statistically significant difference
in postoperative morbidity with regard to the incidence of
permanent hypoparathyroidism or recurrent laryngeal
nerve injury.
The incidence of permanent hypocalcaemia following
TT, which ranges between 0.8% and 3.1%, is not significantly
different from that following STT, which ranges between
0.1% and 0.8%. Our result of 1.5% is comparable to these
figures. Similarly, the incidence of permanent recurrent
laryngeal nerve injury was < 1%. However, both studies
showed a significant difference in the incidence of tempo-
rary hypocalcaemia in favour of STT. If we compare the
temporary complications of hypocalcaemia, which ranged
from 21% to 32.8%, and those of recurrent laryngeal nerve
palsy, which ranged from 1.7% to 5.1%, our study clearly
showed a comparable outcome.
A further argument in the support of TT for toxic goitre
is that it also provides effective initial treatment for any
coexistent occult thyroid cancer. In our study, cancer was
incidentally found in four of 67 (6%) pathology reports.
Barakate et al reported that 32 (2.3%) patients had inci-
dental thyroid cancer.2 Given the benefit of the doubt, 
the only argument in favour of STT is the assumption
that it is associated with a lower complication rate, but it
has an unpredictable outcome with a substantial rate of
recurrence and hypothyroidism.
We conclude that in skilled hands, TT for both Graves’
disease and Plummer’s disease can be performed with
minimal morbidity to the laryngeal nerves and parathy-
roid glands. Our study provides further evidence that TT
is an appropriate operation for toxic goitre and should 
be considered as the procedure of choice for the surgical
treatment of toxic goitre.
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